Please use this identifier to cite or link to this item:
|Title:||Relative inhibitory potency and plasma drug levels of angiotensin converting enzyme inhibitors in the rat.||Austin Authors:||Johnston, Colin I;Cubela, R B;Jackson, B||Affiliation:||University of Melbourne Department of Medicine, Austin Hospital, Heidelberg, Victoria, Australia||Issue Date:||1-Feb-1988||Publication information:||Clinical and Experimental Pharmacology & Physiology; 15(2): 123-9||Abstract:||1. 125I-351A, a tyrosyl derivative of the angiotensin converting enzyme (ACE) inhibitor lisinopril, was used as a radioligand, and radioinhibitor binding and displacement assays have been established. 2. The in vitro potency of a range of ACE inhibitors against rat ACE was determined using the radioinhibitor binding displacement assay. 3. The concentration of an ACE inhibitor needed to displace 50% of 125I-351A bound to rat ACE (ID50) was closely correlated with the concentration needed to inhibit 50% of ACE enzymatic activity (IC50). 4. Radioinhibitor binding displacement assay was used to measure the plasma concentrations of lisinopril, cilazapril and perindopril in rat plasma. 5. Plasma concentrations of lisinopril measured by radioimmunoassay were identical with that measured by radioinhibitor binding assays.||Gov't Doc #:||2856050||URI:||http://ahro.austin.org.au/austinjspui/handle/1/12878||URL:||https://pubmed.ncbi.nlm.nih.gov/2856050||Type:||Journal Article||Subjects:||Angiotensin-Converting Enzyme Inhibitors.blood.pharmacology
Binding, Competitive.drug effects
Iodine Radioisotopes.diagnostic use
Rats, Inbred Strains
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.